Abstract
Each year, a huge number of new cases accounts of TB with added problems due to multidrug resistant TB varieties. Globally, TB is one of the top causes of loss of life among people living with HIV who are more likely than others to get TB infection. Current TB treatment includes long term administration of cocktail of drugs; hence, the development of an alternative armamentarium against TB is the primary requirement. In fact, new drugs with novel activity against mycobacteria are of significant importance in order to combat existing levels of resistance. The present report covers the discovery of a diarylquinoline TB drug, bedaquiline, its antituberculosis effects and mode of action. Clinical studies conducted on bedaquiline which brought it to the accelerated FDA acceptance have been described. This report is of great attention for therapeutic apothecaries working in TB medication growth in terms of creating further diarylquinoline applicants with a wide variety of antimycobacterial results.
Keywords: Antituberculosis drug, bedaquiniline, clinical trials, docking, diarylquinolone, Mycobacterium tuberculosis.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Bedaquiline: A New Hope to Treat Multi-Drug Resistant Tuberculosis
Volume: 14 Issue: 16
Author(s): Rahul V. Patel, Sd. Riyaz and Se Won Park
Affiliation:
Keywords: Antituberculosis drug, bedaquiniline, clinical trials, docking, diarylquinolone, Mycobacterium tuberculosis.
Abstract: Each year, a huge number of new cases accounts of TB with added problems due to multidrug resistant TB varieties. Globally, TB is one of the top causes of loss of life among people living with HIV who are more likely than others to get TB infection. Current TB treatment includes long term administration of cocktail of drugs; hence, the development of an alternative armamentarium against TB is the primary requirement. In fact, new drugs with novel activity against mycobacteria are of significant importance in order to combat existing levels of resistance. The present report covers the discovery of a diarylquinoline TB drug, bedaquiline, its antituberculosis effects and mode of action. Clinical studies conducted on bedaquiline which brought it to the accelerated FDA acceptance have been described. This report is of great attention for therapeutic apothecaries working in TB medication growth in terms of creating further diarylquinoline applicants with a wide variety of antimycobacterial results.
Export Options
About this article
Cite this article as:
Patel V. Rahul, Riyaz Sd. and Park Won Se, Bedaquiline: A New Hope to Treat Multi-Drug Resistant Tuberculosis, Current Topics in Medicinal Chemistry 2014; 14 (16) . https://dx.doi.org/10.2174/1568026614666140929114822
DOI https://dx.doi.org/10.2174/1568026614666140929114822 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Cheminformatics in Anti-Infective Agents Discovery
Mini-Reviews in Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets The Ever Changing Face of Antibiotic Resistance: Prevailing Problems and Preventive Measures
Current Drug Metabolism Novel Drugs Targeting the c-Ring of the F<sub>1</sub>F<sub>O</sub>-ATP Synthase
Mini-Reviews in Medicinal Chemistry New Tuberculostatic Agents Targeting Nucleic Acid Biosynthesis: Drug Design using QSAR Approaches
Current Pharmaceutical Design Relevance of Anxiety and Depression in Chronic Obstructive Pulmonary Disease (COPD)
Current Respiratory Medicine Reviews Assessment and Management of Loose Bodies in the Knee Joint and Related Disease: A Narrative Review
Current Rheumatology Reviews Transcriptional Regulation and Expression of CYP3A4 in Hepatocytes
Current Drug Metabolism Improved Survival with Co-Trimoxazole Prophylaxis among People Living with HIV/AIDS Who Initiated Antiretroviral Treatment in Henan Province, China
Current HIV Research Evaluation and Prediction of Early Alzheimer’s Disease Using a Machine Learning-based Optimized Combination-Feature Set on Gray Matter Volume and Quantitative Susceptibility Mapping
Current Alzheimer Research A Brief Review of the Computational Identification of Antifreeze Protein
Current Organic Chemistry Vesicular Carriers for Skin Drug Delivery: The Pheroid™ Technology
Current Pharmaceutical Design New Chalcones Containing Nucleosides Exhibiting In Vitro Anti-cancer Activities
Letters in Organic Chemistry Present Status and Future Prospects of Chemotherapeutics for Intractable Infections due to Mycobacterium avium Complex
Current Drug Discovery Technologies Meet Our Editorial Board Member
Current Respiratory Medicine Reviews New Antimycobacterial Leads from Multicomponent Hydrazino-Ugi Reaction
Medicinal Chemistry Editorial [Hot Topic: In Silico (Guest Editor: Alexandre G. de Brevern)]
Infectious Disorders - Drug Targets DFT Based QSAR/QSPR Models in the Development of Novel Anti-tuberculosis Drugs Targeting Mycobacterium tuberculosis
Current Pharmaceutical Design XDR-TB, What is it; How is it Treated; and why is Therapeutic Failure so High?
Recent Patents on Anti-Infective Drug Discovery